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Abstract: Cell Cycle and Apoptosis Regulatory Protein (CARP-1/CCAR1) is a peri-nuclear
phosphoprotein that regulates apoptosis via chemotherapeutic Adriamycin (doxorubicin) and a novel
class of CARP-1 functional mimetic (CFM) compounds. Although Adriamycin causes DNA damage,
data from Comet assays revealed that CFM-4.16 also induced DNA damage. Phosphorylation of
histone 2AX (γH2AX) protein is involved in regulating DNA damage repair and apoptosis signaling.
Adriamycin or CFM-4.16 treatments inhibited cell growth and caused elevated CARP-1 and γH2AX
in human breast (HBC) and cervical cancer (HeLa) cells. In fact, a robust nuclear or peri-nuclear
co-localization of CARP-1 and γH2AX occurred in cells undergoing apoptosis. Knock-down of
CARP-1 diminished γH2AX, their co-localization, and apoptosis in CFM-4.16- or Adriamycin-treated
cells. We found that CARP-1 directly binds with H2AX, and H2AX interacted with CARP-1, but not
CARP-1 (∆600–652) mutant. Moreover, cells expressing CARP-1 (∆600–652) mutant were resistant to
apoptosis, and had diminished levels of γH2AX, when compared with cells expressing wild-type
CARP-1. Mutagenesis studies revealed that H2AX residues 1–35 harbored a CARP-1-binding epitope,
while CARP-1 amino acids 636–650 contained an H2AX-interacting epitope. Surface plasmon
resonance studies revealed that CARP-1 (636–650) peptide bound with H2AX (1–35) peptide with a
dissociation constant (Kd) of 127 nM. Cells expressing enhanced GFP (EGFP)-tagged H2AX (1–35)
peptide or EGFP-tagged CARP-1 (636–650) peptide were resistant to inhibition by Adriamycin or
CFM-4.16. Treatment of cells with transactivator of transcription (TAT)-tagged CARP-1 (636–650)
peptide resulted in a moderate, statistically significant abrogation of Adriamycin-induced growth
inhibition of cancer cells. Our studies provide evidence for requirement of CARP-1 interaction with
H2AX in apoptosis signaling by Adriamycin and CFM compounds.
Keywords: CCAR1/CARP-1; γH2AX; apoptosis; chemotherapeutics; cancer cells
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1. Introduction
Apoptosis is an important physiological process that is often utilized during the development
and maintenance of normal tissue homeostasis in organisms. Defects in the pathways that control
apoptosis are implicated as causal or contributing factors in degenerative disorders, auto-immune
diseases, and cancer [1,2]. To date, genetic and biochemical studies identified two major pathways of
apoptosis and a host of biochemical components that function to regulate these pathways in a variety
of cell and organism models [2,3]. A number of extrinsic or intrinsic regulators of apoptosis were
and continue to be exploited to design novel therapeutic strategies [4]. The regulators of apoptosis
signaling, including the ones that are yet to be discovered, therefore, represent attractive avenues for
development of intervention strategies for such pathologies where apoptosis is defective [3,4]. In this
regard, elucidation of novel mechanism(s) of apoptosis signaling would be useful in further defining
cellular apoptotic pathways.
Cell Cycle and Apoptosis Regulatory Protein (CARP-1/CCAR1) is a peri-nuclear phospho-protein
that regulates cell growth and apoptosis signaling [5,6]. CARP-1 functions as a co-activator of
growth signaling via steroid thyroid nuclear receptors and oncogenic signaling via β-catenin, and
co-activates the glucocorticoid receptor for adipocyte differentiation, the anaphase-promoting complex
cyclosome (APC/C) E3 ligase, and tumor suppressor p53 for cell-cycle control and apoptosis [7–10].
High-throughput screening of a chemical library yielded multiple, small-molecule inhibitors (SMIs)
of CARP-1 interaction with the APC2 component of APC/C E3 ligase. These novel compounds,
termed CARP-1 functional mimetics (CFMs), bind with CARP-1, stimulate CARP-1 levels, and
inhibit cell growth in part by inducing cell-cycle arrest and apoptosis [11–18]. CARP-1 tyrosine
(Y)192 was previously found to regulate apoptosis signaling following pharmacologic inhibition of
epidermal growth factor receptors (EGFR), while CARP-1-dependent apoptosis involved activation of
stress-activated protein kinase (SAPK) p38α/β, and caspases-8 and -9 [6,10]. Depletion of CARP-1 on
the other hand confers resistance to apoptosis induced by CFMs, as well as the chemotherapeutics
Adriamycin (doxorubicin), etoposide, and EGFR tyrosine kinase inhibitors (TKIs).
Adriamycin was proposed to exert its cytotoxic effect through a number of mechanisms, including
(a) inhibition of topoisomerase II, resulting in the formation of DNA double-strand breaks, and (b)
formation of intercalating Adriamycin DNA adducts that prevent DNA replication. Overall, DNA
damage is key to Adriamycin-induced cell death. Prior studies reported that phosphorylation of histone
2AX (H2AX) at serine 139 (γ-H2AX) is involved in DNA damage repair and apoptotic signaling by
Ataxia–telangiectasia mutated (ATM)/ ATM and RAD3 related (ATR) and c-jun N-terminal Kinases
(JNKs), respectively [19–21]. Given the critical role of CARP-1 in apoptotic signaling by Adriamycin
and CFM compounds, and the fact that stress-activated kinases like JNKs and phosphoinositide
3-kinase (PI3Ks) are involved in apoptosis signaling by CARP-1 [5,12–18] and H2AX [19–21], we
speculated that the H2AX–CARP-1 axis could be a key for transduction of apoptotic signaling. Our
study reveals that Adriamycin or CFMs promote increase of CARP-1 and γ-H2AX proteins and their
co-localization. Furthermore, mutagenesis studies revealed that a direct interaction of CARP-1 with
H2AX is necessary for apoptosis.
2. Materials and Methods
Cell culture media Dulbecco Modified Eagle Medium (DMEM), Roswell Park Memorial Institute
medium (RPMI)-1640, and the antibiotics (streptomycin and penicillin) were purchased from
Invitrogen Co. (Carlsbad, CA, USA). Ham’s F-12 medium was purchased from Life Technologies,
Inc. (Grand Island, NY, USA), and fetal bovine serum (FBS) was obtained from Denville Scientific Inc.
(Metuchen, NJ, USA). The JNK1/2 inhibitor JNK-IN-8 was obtained from Selleck Chemicals, (Houston,
TX, USA). The CFM-4 compound was obtained from ChemDiv (San Diego, CA, USA). Structure
and synthesis of CFM-4 analog CFM-4.16 was previously described [16]. Clinical-grade Adriamycin
(ADR) was obtained from the Harper Hospital Pharmacy, Wayne State University, Detroit, MI, USA.
Dimethyl sulfoxide (DMSO), 2-deoxy-glucose, 3-4,5-dimethyltiazol-2-yl-2.5-diphenyl-tetrazolium
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bromide (MTT), anti-FLAG tag, and anti-actin antibodies were purchased from Sigma Chemical Co
(St. Louis, MO, USA). The affinity purified, anti-CARP-1 (α1 and α2) polyclonal antibodies were
described previously [5]. Antibodies for Gst-tag, enhanced GFP (EGFP), Myc-tag, phospho, and total
H2AX were purchased from Cell Signaling (Beverley, MA, USA).
2.1. Cell Lines and Cell Culture
Routine maintenance and culture of MDA-MB-468 (lacking estrogen receptor; ER and having
mutant p53) human triple-negative breast cancer (TNBC) cells, human cervical cancer HeLa, human
kidney cancer UOK 262, non-small-cell lung cancer H1975, and HCC827 cells was carried out essentially
as described previously [5,12,13]. Generation and characterization of MDA-MB-468 cells expressing
reduced CARP-1 was described previously [5]. The stable sublines were generated by transfecting
the MDA-MB-468 and Hela cells with the pcDNA3 vector, pcDNA3-CARP-1 wild-type (WT)-myc-His
clone 6.1.2, pcDNA3-CARP-1(∆600–650)-myc-His, pcDNA3-EGFP, pcDNA3-EGFP-H2AX (1–35),
or pcDNA3-EGFP-CARP-1 (636–650) plasmids, followed by selection in the presence of 800 µg/mL
neomycin using described methods [5]. The cell lysates from wild-type, untransfected cells,
neomycin-resistant pools, or individual sublines were then subjected to MTT-based viability, confocal,
immunoprecipitation (IP), and Western blot (WB) analyses as below.
2.2. Cloning of Complementary DNAs
The plasmids for expression of myc-His-tagged wild-type CARP-1 (clone 6.1.2) and CARP-1
anti-sense clone 1.6 were described previously [5]. Additional pcDNA-based plasmids for expression
of CARP-1 (∆600–650), CARP-1 (∆637–667), EGFP, EGFP-CARP-1 (636–650), and EGFP–H2AX
(1–35) were generated by standard molecular biological and cloning manipulations. The open
reading frame of the H2AX complementary DNA (cDNA and H2AX cDNA fragments were cloned
in pGEX-4T-1 vector to generate Gst-H2AX (full-length), Gst-H2AX (1–35), Gst-H2AX (26–60),
Gst-H2AX (47–85), Gst-H2AX (76–110), and Gst-H2AX (101–143) proteins. Additional CARP-1 cDNA
fragments were cloned in pTAT-HA vector (22) to generate His-TAT-HA-tagged CARP-1 (552–654),
His-TAT-HA-tagged CARP-1 (551–580), His-TAT-HA-tagged CARP-1 (571–600), His-TAT-HA-tagged
CARP-1 (591–620), His-TAT-HA-tagged CARP-1 (611–640), His-TAT-HA-tagged CARP-1 (631–660),
and His-TAT-HA-tagged CARP-1 (636–650) proteins. All the recombinant plasmids were sequenced
to confirm the accuracy and validity of various inserts/epitopes. In addition, His-TAT-HA-tagged
CARP-1 (636–652) protein was chemically synthesized to ≥90% purity by Peptides America, Inc.
(Fairfax, VA, USA).
2.3. Immunoprecipitation (IP), Gst-Pulldown, Western Blot (WB), and MTT Assays
Logarithmically growing cells were either untreated or treated with different agents for various
time periods. The cells were lysed to prepare protein extracts. IP was carried out by incubating
approximately 1 mg of the protein lysate with appropriate antibodies. The immunoprecipitates were
then analyzed by SDS-PAGE, followed by WB with respective, interacting protein. For Gst-pulldown,
Gst-H2AX or various His-TAT-HA-tagged CARP-1 peptides were generated in Escherichia coli
(E. coli) BL21 cells essentially as described by us previously [22]. Briefly, the competent E. coli
BL-21 (DE3) pLysS cells were transformed separately with various recombinant pGEX-4T-1 or
pTAT-HA constructs. The transformed cells were then subjected to selection by combined presence
of ampicillin and chloramphenicol; various isolates for each transformation were obtained and
bacterial lysates were characterized for expression of fusion peptides. Cells from each isolate were
grown in 4 mL of LB medium containing ampicillin only until the optical density (OD)600 reached
0.4–0.8. Expression of fusion peptides was induced over 2–4 h incubation periods after Isopropyl
β-D-1-thiogalactopyranoside (IPTG) addition. The cells were harvested, and pellets were stored at
−80 ◦C overnight. The cell pellets were then lysed in 100–400 µL of bacterial protein extraction reagent
(BPER) buffer (Thermo Scientific, Waltham, MA, USA, Cat# 78243) containing 2 µL/mL of 10 units/µL
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DNAse I (Boehringer Mannheim, Fremont, CA, USA, Cat # 776–785), and supernatant checked for
expression of respective fusion peptides by WB. Following confirmation of expression, 5–20 µL of
lysate expressing Gst fusion protein was first incubated with 20 µL of precleared glutathione sepharose
in a final volume of 100 µL at 4 ◦C for 2 h with constant rotation. The sepharose beads were spun
at 800× g for 2 min, and the pellet was washed 2–4 times with 100–200 µL of RIPA buffer (20 mM
Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate,
2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 µg/mL leupeptin)
with 0.5 M NaCl. The beads were spun again as above, and mixed with 5–20 µL of E. coli lysate
expressing His-TAT-HA CARP-1 peptides. The reactions were incubated further at 4 ◦C for 2 h with
constant rotation. The peptide-bound sepharose beads were pelleted and washed with 100–200 µL
of RIPA buffer with 0.1 M NaCl for 2–4 washes. In some cases, additional washes with 0.05 M NaCl
buffer were carried out. After the final wash, the sepharose–protein complexes were spun, and then
re-suspended in SDS loading buffer for electrophoresis on 12–15% SDS PAGE, followed by WB with
appropriate antibodies.
The cell growth inhibition was assessed using an MTT assay following the established protocols
described by us previously [5,10,12–18].
2.4. Synthesis and Purification of Peptides
Affinity purification of the Gst-tagged or His-tagged fusion proteins was carried out essentially
following procedure previously described by us [22]. Briefly, the bacteria expressing respective fusion
protein were cultured in 500 mL of LB medium containing ampicillin until the OD600 reached 0.4–0.6.
Protein expression was induced by addition of IPTG over an additional 2–4-h incubation at 37 ◦C.
Cells were harvested, and pellets were stored overnight at −80 ◦C, and lysed in 4–5 mL of BPER
lysis buffer containing DNAse I as detailed above. The fusion proteins were then purified utilizing
commercially available Gst-sepharose (Pierce Gst purification kit Thermo-fisher Cat#16017) or Ni-NTA
columns (HisPur™ Ni-NTA Chromatography Cartridges, ThermoFisher Cat # 90098) following the
manufacturer’s suggested methods. Fractions containing eluted fusion protein were pooled, and
dialyzed overnight at 4 ◦C in 1–2 L of 1× Tris-buffered saline (BioRad, Hercules, CA, USA) with
multiple buffer changes. Following measurement of protein concentration, the purified protein was
aliquoted and snap-frozen in liquid N2 for storage. In addition, CARP-1 (636–650) and H2AX (1–35)
peptides, each with ≥90% purity, were commercially synthesized followed by labeling of CARP-1
(636–650) with biotin at the amino terminus. We utilized these peptides in the binding studies by
surface plasmon resonance as detailed below. Additionally, His-TAT-HA-tagged CARP-1 (636–650) and
His-TAT-HA-CARP-1 (636–650 scrambled) peptides with >95% purity were commercially synthesized
by Peptides America, Inc., Fairfax, VA, USA.
2.5. DNA Damage and Apoptosis Assay
The DNA damage assay was performed using a comet assay kit 96-well plate (Cell Bio Labs,
CA, USA) as per the manufacturer’s instructions. Briefly, the cell suspension was mixed with the
low-melting agarose at 1:20 ratio and added to the pre-coated 96 well plate. The cells were then
subjected to lysis for 1 h, followed by alkaline electrophoresis. The plate was then washed in 70%
ethanol and Vista Green DNA dye was added. The comets were visualized in Zeiss LSM780 Confocal
microscope. The images were processed using Zeiss ZEN lite software and the comet parameters were
measured using Open comet software.
Caspase activities were measured by utilizing the ApoAlert Caspase profiling plate (Clontech,
Mountain View, CA, USA) essentially following manufacturer’s suggested guidelines.
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2.6. Immunofluorescence Staining and Confocal Microscopy
Cells were plated onto chamber slides one day before treatment. Following treatment of cells
with respective compounds, the adherent cells were fixed with 5% formaldehyde for 10 min and then
washed with phosphate buffered saline (PBS). Samples were blocked (0.5% NP-40, 5% milk powder,
1% fetal bovine serum) for 30 min. After a single wash with PBS, cells were incubated with primary
antibodies for 45 to 60 min. Coverslips were washed with PBS and then incubated with secondary
antibodies for another 45 to 60 min. They were then washed with PBS and mounted with 0.1 µg/mL
4′,6′-diamidino-2-phenylindole (DAPI) containing mounting solution. For confocal imaging, cells were
first fixed with PFA, then stained for CARP-1 by myc-tag antibodies (green), γH2AX antibodies (red),
and DAPI (blue) for nuclear staining. Immunofluorescent or confocal images were taken using a Zeiss
LSM 510 Meta NLO (63×).
2.7. Kinetics of CARP-1–H2AX Interaction
In the first instance, we performed homology modeling of the CARP-1 peptide from positions
631–660 (UniProtKB-Q8IX12; CCAR1_HUMAN) and H2AX peptide from positions 1–35, the region
that interacts with CARP-1, (UniProtKB-P16104; H2AX_HUMAN) using SWISS-MODEL [23]. This
H2AX region is well characterized due to an existing X-ray structure for histone 2A (PDB ID 1S32) [24].
Protein–protein docking was performed using ZDOCK 3.0.2f with IRaPPA re-ranking [25] to dock
the obtained model of CCAR1 with both predicted H2AX models. The top three predictions for
each complex, were further subjected to molecular dynamics (MD) using the AMBER14 package to
relieve clashes resulting from docking [26]. The ff14SB [27] force field was used for proteins and
the TIP3P [28] force field for waters. Each complex was solvated and carefully equilibrated in five
stages to ensure proper hydrogen atom orientation. Simulations were conducted for 24 ns at 300 K
in a periodic boundary with the NVT ensemble using the Andersen thermostat [29]. The SHAKE
algorithm was used to restrain all bonds involving hydrogen. Each trajectory was analyzed using
CPPTRAJ [30] and was subjected to MM-GBSA/PBSA [31] analysis to evaluate the strength of the
protein–protein interaction.
Next, kinetics of CARP-1 binding with H2AX were determined by surface plasmon resonance
(SPR) technology (Profacgen, Shirley, NY, USA). Briefly, CARP-1 (636–650) peptide was dissolved in
water, and various concentrations of CARP-1 peptide were manually printed onto the bare gold-coated
(thickness 47 nm) PlexArray Nanocapture Sensor Chip at 40% humidity. The sensor chip was obtained
from Plexera Bioscience (Seattle, WA, USA). Each concentration was printed in replicate, and each spot
contained 0.2 µL of sample solution. The chip was incubated in 80% humidity at 4 ◦C for overnight, and
rinsed with 10× PBST for 10 min, 1× PBST for 10 min, and deionized water twice for 10 min. The chip
was then blocked with 5% (w/v) non-fat milk in water overnight, and washed with 10× PBST for
10 min, 1× PBST for 10 min, and deionized water twice for 10 min, before being dried under a stream of
nitrogen prior to use. The binding reactions were performed in PBST buffer (0.01 M phosphate-buffered
saline (0.138 M NaCl; 0.0027 M KCl), 0.05% Tween-20, pH 7.4. SPRi measurements were performed
with PlexAray HT (Plexera Bioscience, Seattle, WA, USA). Collimated light (660 nm) passes through
the coupling prism, reflects off the SPR-active gold surface, and is received by the CCD camera. Buffers
and samples were injected by a non-pulsatile piston pump into the 30-µL flow cell that was mounted
on the coupling prim. Each measurement cycle contained four steps: washing with PBST running
buffer at a constant rate of 2 µL/s to obtain a stable baseline, sample injection at 5 µL/s for binding,
surface washing with PBST at 2 µL/s for 300 s, and regeneration with 0.5% (v/v) H3PO4 at 2 µL/s for
300 s. All the measurements were performed at 25 ◦C. The signal changes after binding and washing
(in AU) were recorded as the assay value. Selected protein-grafted regions in the SPR images were
analyzed, and the average reflectivity variations of the chosen areas were plotted as a function of time.
Real-time binding signals were recorded and analyzed using a data analysis module (DAM) obtained
from Plexera Bioscience (Seattle, WA, USA). Kinetic analysis was performed using BIAevaluation 4.1
software from Biacore, Inc. (New York, NY, USA).
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Association and dissociation rate constants were calculated by numerical integration and global
fitting to a 1:1 interaction model and the equation, dRU(t)/dt = kaC(Rmax − RU(t)) − kdRU(t), where
RU(t) is the response at time t, Rmax is the maximum response, C is the concentration of analyte in
solution, ka is the association rate constant, kd is the dissociation rate constant, and RU (0) = 0.
2.8. Statistical Analyses
The statistical analyses were performed using Prism 6.0 software. The data were expressed as
means ± SEM and analyzed using a two-tailed Student’s t-test or one-way ANOVA followed by a post
hoc test. A p-value < 0.05 was considered statistically significant.
3. Results
3.1. Adriamycin or CFMs Inhibit Cell Growth, in Part by Stimulating CARP-1 Expression, Phosphorylation of
JNKs and H2AX, and DNA Damage
A number of our prior studies revealed growth inhibition of a variety of cancer cells by Adriamycin
or the CFM class of compounds [5,10,12–18]. Here, we utilized human TNBC MDA-MB-468 and human
cervical cancer HeLa cells to conduct an MTT-based dose-response analysis using Adriamycin and
CFM compounds. We chose these and other cancer cell lines (see Figure 3 below) to demonstrate
that the DNA damage-induced apoptosis signaling mechanism(s) are functional in cells of different
histological/cancer type and not selective for a particular cell line. Since Adriamycin, CFM-4,
and CFM-4.16 have molecular masses of 543.3, 404.9, and 440.3, respectively, we chose to use
an equimolar dose of each compound in the MTT assays. A dose-response analysis indicated a
robust cell-growth inhibition by a 10 µM dose of Adriamycin in MDA-MB-468 cells (Figure S1A).
Since our prior studies showed that a 10 µM dose of CFM-4.16 also induced a robust inhibition
of growth of MDA-MB-468 cells [16], we utilized a 10 µM dose of each compound for growth
inhibition and WB experiments. A 10 µM dose of either of these compounds inhibited viabilities
of both the cell lines in a time-dependent manner (Figure 1A,B and Figure S1A, Supplementary
Materials). Prior reports established that phosphorylation of H2AX at serine 139 (γ-H2AX) is involved
in DNA damage repair and apoptotic signaling by ATM/ATR and JNKs, respectively [19–21]. Next,
the MDA-MB-468, HeLa, and the kidney cancer UOK 262 cells were treated with a 10 µM dose of the
CFM-4.16 or Adriamycin for various time periods. The cell lysates from the control, untreated, and
treated cells were analyzed by WB for expression of CARP-1, phospho-JNK1/2, phospho-H2AX,
and poly ADP ribose polymerase (PARP) proteins. As shown in Figure 1C and Figure S1B,C
(Supplementary Materials), both the CFM-4.16 and Adriamycin stimulated expression of CARP-1,
phospho-JNK1/2, and phospho-H2AX in a time-dependent manner in all the three cell lines. Please
note that Adriamycin-induced H2AX activation was robust at 12 h in the treatment period. This
H2AX activation by Adriamycin is expected and correlates with current understanding that suggests
activation of H2AX by ATM/ATR kinases often signals DNA repair during low to moderate levels of
DNA damage that will contribute to the cell’s ability to overcome damage and survive [19]. The H2AX
activation is also indicative of DNA damage and involves pro-apoptotic JNKs [20,21]. Our data in
Figure 1C and Figure S1B,C (Supplementary Materials) also show activation of JNKs; however, a robust
JNK activation is co-incident with H2AX phosphorylation following treatments with Adriamycin
or CFM-4.16. Treatment of MDA-MB-468 cells with either of the compounds also provoked PARP
cleavage in a time-dependent manner, with a robust cleaved PARP noted over a 12-h treatment period,
although Adriamycin stimulated PARP cleavage as early as 3 h of treatment (Figure 1C). These findings
collectively demonstrate that both the compounds inhibit cell growth in part by stimulating apoptosis,
and a robust apoptosis activation occurs at 12 h of treatments with respective compounds, co-incident
with a robust increase in CARP-1 levels and activities of JNKs and H2AX.
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arrowhead on the left side of each blot. The approximate location of various molecular-weight markers
is indicated on the right side of each blot; kDa, kilodalton.
Adriamycin is well known to i DNA damage. Given the critical role of CARP-1 in apoptotic
signalin by Adriamycin and CFM compounds, and the fact that stress-activ ted protein kinases
(SAPKs) p38 and JNKs are activated in apoptosis signaling by CFM-4.16 [6,12–18], we next determined
whether CFM-4.16 also provoked DNA damage. We treated MDA-MB-468 and HeL cells with a
10 µM dose of Adriamycin or CFM-4.16 for 1, 3, 6, and 12 h, followed by assessment of damaged
DNA by the comet assay as described in Sectio 2. The presence of comet-like tails that contain the
fragmented cellular DNA is a well-known marker/indicator of apoptosis [32]. We measured the
com t parameters such as percentage tail DNA and mean tail mo nt. As sh wn in the Figure 2A–D,
Table S1, and Figure S2A,B (Supplementary Materials), the p centage of tail DNA, as well as tail
moment, significantly increased in cells treated with A riamycin or CFM-4.16 in a time-dependent
manner. Of note is the fact t at Adriamycin nd relate anthracyclines intercalate between DNA bases
and trap topoisomerase II (TopoII) in the double-strand cl avage form, thus introducing double-strand
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breaks (DSBs) due to TopoII poisoning [33]. It remains to be clarified whether CFM-4.16 also targets
cellular DNA and/or the associated DNA repair complex protein(s) to introduce DNA strand breaks,
or activates caspase-activated DNAses to breakdown cellular genomic DNA. Nevertheless, our data
in Figures 1 and 2 suggest that, similar to promotion of DNA damage by Adriamycin and CFM-4.16,
molecular mechanisms of H2AX-dependent apoptosis signaling likely overlap between the two agents.
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3.2. CARP-1 Interacts with H2AX, and Knock-Down of CARP-1 Leads to Reduced H2AX in Cells Treated with
Adriamycin or CFM-4.16
Since CARP-1 depletion prevented apoptosis due to Adriamycin or the CFM
compounds [5,7,10,12–18], we tested whether CARP-1 interacted with H2AX and the extent to which
this interaction regulated H2AX activation during apoptosis signaling. Co-immunoprecipitation
and WB studies with lysates from MDA-MB-468, UOK262, and non-small-cell lung cancer (HCC827
and H1975) cells revealed CARP-1 interaction with H2AX (Figure 3A). We next clarified whether
CARP-1 is required for H2AX activation. As shown in WB analyses in Figure 3B, Figure S3A, and
immunofluorescence (IF) analysis in Figure S3B (Supplementary Materials), while Adriamycin or
CFM-4.16 caused a robust increase in CARP-1 levels and γH2AX in MDA-MB-468 and HCC827cells,
knock-down of CARP-1 abrogated CARP-1 and γH2AX increase by either of the compounds,
suggesting a requirement for CARP-1 in activation of H2AX.
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3.3. CARP-1 (636–650) Binds with H2AX (1–35)
We next carried out mutagenesis-based studies to map the interacting epitopes of CARP-1 and
H2AX proteins. In the first instance, we generated multiple, neomycin-resistant, MDA-MB-468
stable cell lines expressing pcDNA3 vector, myc-His-tagged wild-type CARP-1, or CARP-1 mutants
harboring in-frame deletion of CARP-1 amino acids 600–650 or 637–667 essentially as detailed in
Section 2 and our prior publication [6]. The CARP-1 interaction with H2AX was then investigated
by immunoprecipitation and WB analyses. As shown in Figure 4A, H2AX interacted with wild-type
CARP-1 but not either of the CARP-1 mutants that harbored deletion of amino acids 600–650 or
637–667, suggesting that the H2AX-interacting epitope of CARP-1 likely resided within amino acids
637–650. Additional immunoprecipitation and WB analyses revealed that, while Adriamycin or
CFM-4.16 treatments induced a robust interaction of wild-type CARP-1 with γH2AX, in-frame
deletion of CARP-1 amino acids 600–650 abrogated CARP-1 interaction with γH2AX (Figure 4B,C).
Furthermore, consistent with our findings in Figure 1, treatments with Adriamycin or CFM-4.16 caused
a time-dependent stimulation of JNK1/2 and H2AX activatio in cells ov rexpressing myc-His-tagged
CARP-1 (Figure 4D,E). However, treatments with either of t s failed to activate JNK1/2
or H2AX in cells stably expressing CARP-1 muta t e eletion of amino acids 600–650
(Figure 4D,E, Figure S4, upplementary Materials). Although in ibition of CARP-1 binding with H2AX
abrogated activation of JNK1/2 by Adriamycin or CFM-4.16 (Figure 4D,E), we next clarified whether
activation of JNK1/2 was required for H2AX phosphorylation. For this purpose, we utilized JNK-IN-8,
an allosteric inhibitor of JNK activation, and utilized a 5 µM dose of this compound for cell viability
and protein expression studies essentially as described previously [34]. Treatments of MDA-MB-468
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cells with Adriamycin, JNK-IN-8, or a combination caused elevated levels of CARP-1, while exposure
to JNK-IN-8 resulted in total loss of JNK activation (Figure 4F). Adriamycin treatment, however,
caused a robust increase in γH2AX, while combined presence of JNK-IN-8 and Adriamycin resulted
in reduced levels of γH2AX (Figure 4F). Interestingly, exposure to JNK-IN-8 alone also stimulated
an increase in CARP-1 levels. Although MDA-MB-231 HBC cells that were treated with JNK-IN-8
had significantly reduced viabilities when compared with their untreated counterparts [34], whether
elevated CARP-1 in cells treated with JNK-IN-8 occurs due to inhibition of JNKs or potential, off-target
stress-inducting effects remains to be clarified. Nevertheless, these data collectively demonstrate that
CARP-1 interaction with H2AX is likely necessary for activation of JNK1/2 and H2AX by Adriamycin
or CFM-4.16, and JNK activation is required for Adriamycin-dependent phosphorylation/activation of
H2AX. Moreover, Adriamycin induces expression of CARP-1 and a faint activation of JNK1/2 and
H2AX seems to occur in CARP-1 (∆600–650) expressing cells following treatments with Adriamycin or
CFM-4.16 (Figure 4C,D), and this is likely due to the endogenous CARP-1-JNK1/2-H2AX signaling.
However, since overall JNK1/2 and H2AX activation by Adriamycin or CFM-4.16 is diminished in
cells overexpressing CARP-1 (∆600–650) when compared with their wild-type expressing counterparts
(Figure 4C,D), it is possible that Adriamycin induction of endogenous CARP-1–JNK1/2–H2AX
apoptosis signaling is insufficient in promoting apoptosis in CARP-1 (∆600–650) cells. Collectively,
overexpression of CARP-1 (∆600–650) would block Adriamycin-dependent JNK1/2 activation and, in
turn, likely functions to promote survival.
We further clarified whether CARP-1 bound to H2AX directly by utilizing various E. coli-expressed
His-TAT-HA-tagged CARP-1 and Gst-tagged H2AX peptides as detailed in Section 2. The data revealed
that His-TAT-HA-CARP-1 (552–654) and His-TAT-HA-CARP-1 (631–660) bound with Gst-H2AX
protein (Figure 5A), while His-TAT-HA-CARP-1 (631–660) peptide bound with Gst-H2AX and
Gst-H2AX (1–35) proteins (Figure 5B). Together with data in Figure 4B, our mutagenesis and
peptide-binding studies demonstrate that CARP-1 (636–650) and H2AX (1–35) regions harbor minimal
epitopes necessary for CARP-1–H2AX binding. We then generated MDA-MB-468 and Hela sublines
that stably express EGFP-tagged H2AX (1–35) or EGFP-tagged CARP-1 (636–659) fusion proteins
(Figure S5A,B, Supplementary Materials) to demonstrate in-cell interaction of the CARP-1 (636–650)
peptide with endogenous H2AX, and H2AX (1–35) peptide with endogenous CARP-1. Cell lysates
from the MDA-MB-468 sublines that stably express EGFP vector or EFGP-CARP-1 (636–650) were
first subjected to immunoprecipitation using anti-EGFP antibodies followed by WB analysis using
anti-H2AX antibodies. Figure 5C shows a robust, in vivo (in-cell) interaction of CARP-1 (636–650)
with endogenous H2AX protein. In an analogous experiment, MDA-MB-468 sublines that stably
express EGFP vector or EFGP-H2AX (1–35) were subjected to immunoprecipitation using anti-EGFP
antibodies followed by WB analysis using anti-CARP-1 (α2) antibodies. Figure 5D shows a robust,
in vivo interaction of H2AX (1–35) with endogenous CARP-1.
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Figure 4. Deletion of CARP-1 amino acids 600–650 abrogates H2AX–CARP-1 interaction, and
activation of H2AX and JNKs by Adriamycin or CFM-4.16. (A) Approximately 1 mg of cell
lysate from each of the indicated cells was subjected to immunoprecipitation using anti-myc tag
antibodies. The immunoprecipitates were then analyzed with WB by probing the membrane with
anti-myc tag (for CARP-1) (top autoradiograph). The membrane was subsequently re-probed with
anti-H2AX antibodies to ascertain presence of H2AX (middle autoradiograph). The whole-cell
lysates were separately analyzed with WB to determine endogenous H2AX in the respective cell
line (Lower autoradiograph). (B) Cells stably expressing myc-His-tagged CARP-1 or its ∆600–650
mutant were either untreated (Control), or treated with Adriamycin or CFM-4.16 for noted dose and
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time. Cell lysates were analyzed by immunoprecipitation using anti-myc tag or immunoglobulin
G (IgG), followed by WB analysis using anti-myc tag (for CARP-1), γH2AX, or H2AX antibodies.
(C) Cells were treated as in (B), and lysates were analyzed with WB using γH2AX and H2AX antibodies.
(D,E) Cells stably expressing myc-His-tagged CARP-1 or its ∆600–650 mutant were either untreated
(0), or treated with Adriamycin or CFM-4.16 for noted dose and time. Cell lysates were analyzed
with WB using anti-γH2AX or phospho-JNK1/2 antibodies followed by probing of the respective
membranes with antibodies for total H2AX and JNK1/2. myc tag (for CARP-1), or γH2AX antibodies.
(F) MDA-MB-468 cells were either untreated (Control), or treated with noted agents. Cell lysates were
analyzed with WB as described in Section 2 for levels of CARP-1, phospho- and total JNK1/2, γH2AX,
and H2AX. The WB membranes were subsequently probed with anti-actin antibodies to assess equal
loading. The presence of respective proteins in (A–F) is indicated by an arrowhead on the left side of
each blot. The approximate location of various molecular-weight markers is indicated on the right side
of each blot; kDa, kilodalton.Cancers 2019, 11, x 13 of 24 
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expression in E. coli BL-21 cells essentially as described in Section 2. (A) Gst-H2AX protein was
immobilized on glutathione sepharose followed by incubation indicated CARP-1 peptides. Following
stringent washing, the bound proteins were analyzed with WB using anti-HA (upper) or anti-Gst
(middle) antibodies. The lower blot shows respective HA-tagged CARP-1 peptides used as input.
(B) Indicated Gst-tagged H2AX peptides were firstly immobilized on glutathione sepharose followed
by incubation with His-TAT-HA-CARP-1 (631–660) peptide. Stringent washing and WB analyses
were performed as in panel A. (C,D) Approximately 1 mg of cell lysate from each of the indicated
cells stably expressing EGFP, EGFP-CARP-1 (636–650), or EGFP-H2AX (1–35) was subjected to
immunoprecipitation using anti-EGFP antibodies. The immunoprecipitates were then analyzed with
WB by probing the membrane with anti-EGFP, anti-H2AX, or anti-CARP-1 (α2) antibodies as noted
in the upper boxes in (C,D). The whole-cell lysates were separately analyzed with WB to determine
endogenous H2AX and CARP-1 levels in the respective cell line (lower boxes in( C,D)). The presence of
respective proteins is indicated by an arrowhead on the left side of each blot. The approximate location
of various molecular-weight markers is indicated on the right side of each blot; kDa, kilodalton.
3.4. Kinetics of CARP-1 (636–650) Binding with H2AX (1–35)
We conducted computational modeling and surface plasmon resonance studies to investigate the
binding kinetics of CARP-1 and H2AX peptides. We firstly performed computational modeling studies
utilizing various models and algorithms in conjunction with CARP-1 residues 631–660 and H2AX
residues 1–35 as detailed in Section 2. Although a crystal structure of CARP-1 is yet to be resolved,
the structural prediction using SWISS-MODEL (Figure S6A, Supplementary Materials) indicated 48%
homology to the SAP domain of E1B-55kDa-associated protein 5 (PDB ID: 1ZRJ; [35]) The crystal
structure of H2AX, on the other hand, is well characterized. Based on an existing H2AX X-ray structure,
two structural models were produced (Figure S6B, Supplementary Materials). The computational
analyses were then conducted to perform protein–protein docking using the model of CARP-1 with
both predicted H2AX models as detailed in Section 2. The conformational stability of each complex was
then analyzed as, presumably, the more tightly bound or constrained a complex, the less fluxionality
might be expected. Furthermore, relieving steric clashes should increase the backbone root mean
square deviation (RMSD) significantly when considering this small structure. This was reflected in
the backbone RMSD throughout the simulation (Figure 6 and Figure S6, Supplementary Materials).
Even after equilibration and heating, the backbone RMSD was significantly higher than it would be for
an entire protein that would otherwise have less backbone flux [36,37]. Complex 1 of CARP-1/H2AX
model A (Figure 6A; top row) initially showed a very small change in structure; however, it quickly
adopted a very different conformation from the initial structure. This was reflected by the large, steady
RMSD. In complex 2 (Figure 6A; middle row), two different conformations occurred. Initially, the
protein was stable with a backbone RMSD of 5.5 Å compared to the starting structure. After 20 ns, it
began to adopt a significantly different conformation as can be seen by the presence of a second spike
in the conformation frequency. The third complex (Figure 6A; bottom row) was stable throughout the
entire simulation as indicated by the presence of only one dominant conformer. Most importantly, all
three complexes remained bound throughout the entire simulation. We also analyzed the CARP-1
complex with H2AX model B (Figure 6B). Except for the third pose (bottom row) in Figure 6B, a similar
trend was observed for top and middle rows as noted for the CARP-1/H2AX model in Figure 6A
complexes. The top pose in Figure 6B displays more conformational instability as seen through the
larger number of peaks observed in the histogram, although there is one dominant conformation
observed at an RMSD of 10.4 Å. The middle complex in Figure 6B was much more stable throughout
the simulation with a single dominant conformer at approximately 5.9 Å RMSD, as also was the third
complex in the bottom row of Figure 6B. By contrast, the third pose was very unstable as shown
through not only the large number of conformations, but also through the steadily increasing RMSD.
In this simulation, the two peptides dissociated from each other [35] resulting in the increasing RMSD.
We did not consider this pose in subsequent MM-PBSA/GBSA analysis.
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To determine whether these two proteins have potential to interact in a biological setting, we
subjected each complex to MM-PBSA/GBSA analysis (Table 1). Calculations were computed from
200 poses within the last 5 ns of the simulation. Due to the larger flexibility afforded to small
peptides compared to an entire protein, the energy calculated at each pose can be significantly different
compared to nearby poses. This was reflected in the large standard deviations observed for each
complex. However, the binding energies were relatively close to each other and of significantly high
magnitude to suggest that protein–protein interaction between these two regions of CARP-1 and H2AX
is possible. Absolute binding energies were shown across the different complexes; however, these
values were not exact and only served as a comparison to each other for reference.
Table 1. Calculation of the binding energies (BE) (Kcal/M) of the CCAR1/H2AX model interactions
using MM-PBSA and MM-GBSA.
Approaches
CCAR1/H2AX Model A CCAR1/H2AX Model B
1 2 3 1 2
B.E. Std. Dev. B.E. Std. Dev. B.E. Std. Dev. B.E. Std. Dev. B.E. Std. Dev.
MM-PBSA −31.4 5.39 −21.8 3.97 −37.8 6.80 −24.5 6.00 −44.2 5.46
MM-GBSA −27.0 6.44 −17.6 3.47 −25.5 8.56 −20.5 5.07 −37.6 6.04
The predicted kinetics of interaction of CARP-1 (631–660) and H2AX (1–35) epitopes was further
validated by utilizing respective, chemically synthesized peptides to determine their in-solution
binding by surface plasmon resonance technology as described in Section 2. As shown in Figure 6C,
this experiment revealed an equilibrium dissociation constant (Kd Value) of 1.26 × 10−7 M.
(Ka = 2.32 × 103 M−1·s−1, Kd = 2.92 × 10−4·s−1). Collectively, our data in Figures 5 and 6 demonstrate
that binding of CARP-1 and H2AX proteins involved a single, respective epitope, and that binding of
the CARP-1 (636–650) and H2AX (1–35) regions was direct and strong.
Cancers 2019, 11, x 15 of 24 
Table 1. Calculation of the binding energies (BE) (Kcal/M) of the CCAR1/H2AX model interactions 
using MM-PBSA and MM-GBSA. 
Approaches 
CCAR1/H2AX Model A CCAR1/H2AX Model B 
1 2 3 1 2 
B.E. Std. Dev. B.E. Std. Dev. B.E. Std. Dev. B.E. Std. Dev. B.E. Std. Dev. 
MM-PBSA −31.4 5.39 −21.8 3.97 −37.8 6.80 −24.5 6.00 −44.2 5.46 
MM−GBSA −27.0 6.44 −17.6 3.47 −25.5 8.56 −20.5 5.07 −37.6 6.04 
The predicted kinetics of interaction of CARP-1 (631–660) and H2AX (1–35) epitopes was further 
validated by utilizing respective, chemically synthesized peptides to determine their in-solution 
binding by surface plasmon resonance technology as described in Section 2. As shown in Figure 6C, 
this experiment revealed an equilibrium dis ociation constant (Kd Value) of 1.26 × 10−7 M. (Ka = 2.32 × 
103 M−1·s−1, Kd = 2.92 × 10−4·s−1). Collectively, our data in Figur s 5 and 6 demonstrate that binding of 
CARP-1 and H2AX proteins involved a single, respective epitope, and that binding of the CARP-1 
(636–650) and H2AX (1–35) regions was direct and strong. 
 
Figure 6. Cont.
Cancers 2019, 11, 221 15 of 24
Cancers 2019, 11, x 16 of 24 
 
 
Figure 6. Computational analyses of H2AX (1–35) binding with CARP-1 (631–650). Backbone RMSD 
calculations and conformation frequency analysis for the three poses (top, middle, and lower boxes) 
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resonance sensogram showing binding of noted CARP-1 and H2AX peptides (inset) as detailed in 
Section 2. 
Figure 6. Computational analyses of H2AX (1–35) binding with CARP-1 (631–650). Backbone RMSD
calculations and conformation frequency analysis for the three poses (top, middle, and lower boxes) of
the docked CARP-1 (model A)/H2AX complex (A), and CARP-1 (model B)/H2AX complex (B). Each
analysis was completed over 24 ns of simulation for each complex. (C) Surface plasmon resonance
sensogram showing binding of noted CARP-1 and H2AX peptides (inset) as detailed in Section 2.
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3.5. Interference with CARP-1–H2AX Binding Abrogates Cell-Growth Inhibition by Adriamycin or
CFM Compounds
Our next objective was to analyze the biological significance of the CARP-1–H2AX interaction
in cells. For this purpose, we utilized MDA-MB-468 and HeLa cell lines that stably express
myc-His-tagged wild-type CARP-1 or CARP-1 (∆600–650)-myc-His proteins as detailed in Figure S4
(Supplementary Materials). These sublines were then either untreated (Control, DMSO), or treated
with Adriamycin or CFM-4 compound. Cells expressing CARP-1 (∆600–650) mutant were resistant
to inhibition by CFM-4 or ADR when compared with their WT CARP-1-expressing counterparts
(Figure 7A and Figure S7A, Supplementary Materials). Next, we measured activation of caspases as
an apoptosis readout in cells expressing myc-His-tagged wild-type CARP-1 or CARP-1 (∆600–650)
proteins that were either untreated or treated with Adriamycin or CFM compounds as detailed in
Section 2. We utilized a lower, 4–5 µM dose of Adriamycin or CFM compounds because a 10 µM
Adriamycin dose caused interference in signal output/readout in this particular assay, likely due
to background fluorescence that is emitted by higher dose of Adriamycin. Although Adriamycin
has a maximum excitation and emission wavelength of 470 and 560 nm, respectively [38], we found
significant fluorescence emission in cells treated with 10 µM Adriamycin at a 380-nm excitation
wavelength. Moreover, since caspase activation precedes apoptotic cell death, we utilized a lower
dose of Adriamycin to permit a robust measurement of optimal caspase activation in cells undergoing
moderate apoptosis with lower/minimal interference by Adriamycin-induced fluorescence signals.
Our data revealed that there was an overall reduction in activation of caspases-3, -8, -9, and -2 in
Adriamycin-treated CARP-1 (∆600–650) cells when compared with their wild-type CARP-1-expressing
counterparts (Figure 7B). We then clarified whether stable expression of CARP-1 (636–650) or H2AX
(1–35) peptides, which in principle will compete for the endogenous CARP-1-H2AX interaction, would
also abrogate inhibitory effects of Adriamycin or CFM compounds. Here, we utilized MDA-MB-468
and HeLa cell lines that stably express EGFP, EGFP-CARP-1 (636–650), or EGFP-H2AX (1–35)
proteins, as described in Figure 5 above. Cells expressing EGFP-CARP-1 (600–650) or EGFP-H2AX
(1–35) fusion proteins were resistant to inhibition by CFM-4.16 or ADR when compared with their
respective, EGFP-expressing counterparts (Figure 7C,D and Figure S7B,C, Supplementary Materials)
that again was due in part to an overall reduction in activation of caspase-3 (Figure 7E,F). Further
flow-cytometric analysis of the MDA-MB-468 cells expressing EGFP or EGFP-CARP-1 (636–650)
that were either untreated (control), or treated with Adriamycin or CFM-4.16 were conducted to
monitor apoptosis. As shown in Figure S7D (Supplementary Materials), Adriamycin or CFM-4.16
treatments resulted in a generally higher percentage of EGFP-expressing cells undergoing apoptosis
when compared with similarly treated EGFP-CARP-1 (636–650)-expressing counterparts. Whether
competition for the endogenous CARP-1–H2AX interaction by stably expressed H2AX (1–35) peptide
altered H2AX activation and/or translocation to confer resistance to Adriamycin was next clarified
by confocal analyses. MDA-MB-468 or HeLa cells that express EGFP or EGFP-H2AX (1–35) were
separately treated with Adriamycin, and presence of CARP-1 and γH2AX was determined by
immuno-cytochemical staining followed by photography by a confocal microscope as described
in Section 2. Hyper-phosphorylation of H2AX by JNKs and consequent γH2AX cytoplasmic
distribution was previously shown to promote apoptosis following DNA damage [19–21]. The confocal
analyses shown in Figure S6E (Supplementary Materials) revealed increased nuclear presence of
γH2AX in Adriamycin-treated, cells that express EGFP-H2AX (1–35) when compared with their
EGFP-expressing, Adriamycin-treated counterparts. Since nuclear presence of γH2AX is often
associated with DNA damage repair, it is likely then that the nuclear presence of γH2AX in EGFP-H2AX
(1–35) cells contributes to more effective repair of Adriamycin-induced DNA damage and, in turn,
promotes cell survival in the presence of Adriamycin when compared with the EGFP-expressing,
Adriamycin-treated cells.
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Figure 7. Disruption of H2AX interaction it P-1 results in enhanced viabilities of CFM-4-,
CFM-4.16-, or Adriamycin-treated cells in part due to reduced apoptosis. (A,C,D) Indicated
MDA-MB-468 cell lines were treated with DMSO (Control), or with the noted dose and time of
Adriamycin, CFM-4, or CFM-4.16 compounds. Determination of viable/live cells was carried
out by MTT assay as described in Section 2. (B,E,F) Cell lysates derived from vehicle DMSO
(Control), or CFM-4-, CFM-4.16-, or Adriamycin-treated cells were added to the wells that had
immobilized fluorogenic substrates of noted caspases. The fluorescence released from the activated
caspase-dependent cleavage of respective substrate was detected by a plate reader at the excitation and
emission wavelengths of 380 nm and 460 nm, respectively, as detailed in Sectio 2. The columns in
bar ch ts in panels A, C, D and B, D, F represent means of three and two independen experiments,
respectively; bars, SE. For panels C and D, * p < 0.05, **p < 0.01 and *** p≤ 0.001 relative to the respective
EGFP vector subline. For panels E and F, *** p ≤ 0.05 relative to the respective EGFP vector subline.
We further tested hether and the extent to which transient and ectopic expression of CARP-1
(636–650) peptide would also interfere with the cell-growth inhibition by Adriamycin. For this purpose,
we utilized affinity purified His-TAT-HA-tagged EGFP, the His-TAT-HA-tagged CARP-1 (636–650)
peptide, and His-TAT-HA-CARP-1 (636–650 scrambled) peptides. The wild-type MDA-MB-468 or
HeLa cells were pre-incubated with His-TAT-HA-EGFP or His-TAT-HA-CARP-1 (636–650) proteins,
and presence of GFP and CARP-1 (636–650) was determined by immuno-cytochemical staining
followed by photography using a confocal microscope as above. As expected, EGFP and CARP-1
(636–650) proteins were predominantly present in the c toplasmic region (Figure S8A,B, Supple entary
Materials). Next, the cells were transduced with EGFP, CARP-1 (636–650), or CARP-1 (636–650,
scrambled) proteins and were separately treated with Adriamycin for various times followed by
determination of their viabilities with an MTT-based assay as detailed in Section 2. Expression of
CARP-1 (636–650) peptide resulted in a moderate, statistically significant increase in viabilities as
compared with respective EGFP-expressing counterparts (Figure 8A,B). Next, the MDA-MB-468
cells were firstly pre-incubated with His-TAT-HA-CARP-1 (636–650), His-TAT-HA-CARP-1 (636–650
scrambled) peptides, or not (Control). The cells were then separately treated with Adriamycin,
and stai ed f r presence of respective peptide and γH2AX as described in Section 2. Presence of
His-TAT-HA-CARP-1 (636–650), but not its scrambled version, resulted in increased pres nce of
γH2AX (top row, Figure 8C), when compared with cells th t had either no peptide (Control) or were
pre-incubated with His-TAT-HA-CARP-1 (636–650 scrambled) peptide (Figure S9, Supplementary
Materials). Data in Figure 8 would suggest that CARP-1 (636–650) peptide likely competes for
Adriamycin-induced CARP-1/H2AX interaction that results in reduced growth inhibition, and an
overall increase in γH2AX that likely permits DNA repair and cell survival.
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Figure 8. Ectopic expression of TAT-CARP-1 (636–650) peptide results in enhanced viabilities of
Adriamycin-treated cells. MDA-MB-468 (A) or HeLa (B) cells were pre-incubated with 300 µg/mL
indicated peptides for 72 h, followed by treatments with the noted dose and time of Adriamycin.
Determination of viable/live cells was carried out using an MTT assay as described in Section 2. The bar
charts in panels A and B represent means of three and two independent experiments, respectively;
bars, SE. (C) Indicated cells were either pre-incubated with 6 µg/mL indicated peptides for 72 h
or not (Control), followed by treatments with Adriamycin as noted. Cells were then processed for
immunofluorescence staining for TAT-CARP-1 peptide (red), γH2AX (green), and DAPI (blue) as
detailed in Section 2 and Figure S3 (Supplementary Materials). Insets in C show enlarged areas of
respective photomicrographs to indicate presence of TAT-CARP-1 peptide and γH2AX in respective
columns. The insets in the top and middle rows of the merge column show co-localization of
TAT-CARP-1 peptide, and γH2AX (magnification: 250×).
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4. Discussion
Studies from our laboratory and others demonstrated that CARP-1/CCAR1 is a biphasic
regulator of cell growth and apoptosis signaling [11]. Although CARP-1 functions as a co-activator of
steroid/thyroid nuclear receptors to promote growth [7], and co-activates β-Catenin in colon cancer
cells to promote metastasis [8], its transcriptional co-activation of tumor suppressor p53 regulates
apoptosis by Adriamycin [7]. Adriamycin action involves pleiotropic effects that include (a) activation
of signal transduction pathways, (b) generation of reactive oxygen species (ROS), (c) stimulation of
apoptosis, and (d) inhibition of DNA topoisomerase II catalytic activity [39]. Although Adriamycin
activates intrinsic apoptotic pathways, and the endogenous apoptosis modulators Bcl-2 and p53
regulate Adriamycin-dependent apoptosis [40,41], a cellular lipid messenger, ceramide, generated by
Ariamycin was recently revealed to contribute to the development of resistance in a number of cancer
cell types [42]. Nevertheless, inhibition of topoisomerase II by Adriamycin results in the formation
of DNA double-strand breaks (DSBs) while formation of intercalating Adriamycin DNA adducts
prevent DNA replication [39–41]. Overall, DNA damage is key to Adriamycin-induced cell death.
Our data from the comet assay revealed, for the first time, that CFM compounds function in part
by inducing DNA damage in the cancer cells. Of note is the fact that, although Adriamycin and
related anthracyclines function in part by inducing DSBs, it is unclear whether CFM-4.16 also targets
cellular DNA and/or the associated DNA repair complex protein(s) to introduce DSBs or activate
caspase-activated DNAses to break down cellular genomic DNA.
A number of reports revealed that DNA damage repair and apoptotic signaling by ATM/ATR
and JNKs, respectively, involve phosphorylation of H2AX at serine 139 (γ-H2AX). The activation
of H2AX by ATM/ATR kinases facilitates DNA repair during low to moderate levels of DNA
damage that will likely allow cells to overcome damage and survive. Our findings in Figure 1
show that the H2AX activation was co-incident with increased CARP-1 and activation of pro-apoptotic
JNKs. Since DSB-induced apoptosis involves serine 139 phosphorylation of H2AX by JNKs [21],
we speculated that CARP-1 was involved in regulating apoptosis by JNK–H2AX signaling. Our
co-IP/WB analyses revealed interaction of CARP-1 and H2AX (Figure 3), while knock-down of
CARP-1 prevented activation of H2AX by Adriamycin or CFM-4.16 compound. Further mutagenesis
studies in Figures 4 and 5 confirmed H2AX–CARP-1 interaction and direct binding, and requirement
of their interaction in JNK activation by Adriamycin or CFM-4.16. Additionally, our data demonstrate
that CARP-1 amino acids 636–650 and H2AX residues 1–35 harbor minimal epitopes for their respective
binding with robust dissociation kinetics.
Our studies presented in Figure 7 demonstrate, for the first time, that abrogation of H2AX–CARP-1
interaction interferes with the inhibitory effects of Adriamycin or CFM compounds, in part through
attenuation of apoptosis. More importantly, overexpression of H2AX (1–35) or CARP-1 (636–650)
peptides conferred resistance to inhibition by Adriamycin or CFM-4.16. Since these peptides are
expected to target the endogenous H2AX–CARP-1 interaction, our “proof-of-concept” studies in
Figure 7 demonstrate that H2AX–CARP-1 interaction and consequent signaling could potentially
be targeted to attenuate apoptosis signaling. Cardiac and nephro-toxicities associated with many
chemotherapeutics including the topoisomerase toxins [33] are well known to prevent optimal
utilization in the clinic. If proven, our small peptides or their futuristic small-molecule mimetics could,
in principle, be useful means to minimize inhibitory effects of chemotherapy such as Adriamycin in
non-cancer, normal tissues of the host.
CARP-1/CCAR1 and its paralog deleted in breast cancer 1 (DBC1, CCAR2, KIAA1967) are large
proteins that share many highly conserved protein domains, and have similar patterns of predicted
disorder in less-conserved intrinsically disordered regions [43]. DBC1 was previously shown to
regulate mitochondrial apoptosis during TNFα-mediated death signaling [44]. Additional reports
revealed that DNA damage induced by ionizing radiation or topoisomerase toxin etoposide stimulated
DBC1 Thr454 phosphorylation by ATM/ATR kinases. This functional modification of DBC1 promotes
binding with deacetylase SIRT1, and consequent SIRT1 inactivation results in p53-dependent apoptotic
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response [2]. DBC1 was also found to function as a tumor suppressor in part through its ability to
regulate p53 stability by competing with MDM2 [45]. In this regard, DBC1 activation of p53 response
overlaps with the Adriamycin-induced CARP-1/CCAR1 co-activation function of p53 [7]. Although
ATM/ATR kinases regulate DNA damage response (DDR) in part by stimulating γH2AX, and since
CARP-1 and DBC1 proteins share many conserved domains, our additional co-immunoprecipitation
studies (Figure S10, Supplementary Materials) revealed that DBC1 does not interact with wild-type
H2AX or H2AX (1–35) epitope. These findings would suggest that H2AX-mediated apoptosis
induced by DNA-damage signaling selectively involves H2AX binding with CCAR1/CARP-1 but not
CCAR2/DBC1.
5. Conclusions
In conclusion, our studies demonstrate a novel mechanism of apoptosis signaling that is
dependent on the unique interaction of CARP-1 and H2AX proteins. Disruption of this interaction
could potentially be a useful mechanism to interfere with apoptosis following DNA damage. Our
proof-of-concept studies could potentially be extended to cardiomyocytes, and represent a rational
means to minimize systemic toxicities, particularly to the cardiac tissues following treatments with
DNA-damage-inducing chemotherapies such as Adriamycin. If proven, these mechanism-based,
apoptosis-preventing strategies could help optimize anti-cancer efficacy of chemotherapeutics while
lowering their systemic/cardiotoxicities.
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